These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9663890)

  • 1. Natural history of Staphylococcus aureus nasal carriage and its relationship to exit-site infection.
    Turner K; Uttley L; Scrimgeour A; McKewan A; Gokal R
    Perit Dial Int; 1998; 18(3):271-3. PubMed ID: 9663890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD).
    Davies SJ; Ogg CS; Cameron JS; Poston S; Noble WC
    Perit Dial Int; 1989; 9(1):61-4. PubMed ID: 2488184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staphylococcus aureus CAPD-related infections are associated with nasal carriage.
    Lye WC; Leong SO; van der Straaten J; Lee EJ
    Adv Perit Dial; 1994; 10():163-5. PubMed ID: 7999818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Staphylococcus nasal colonization and HIV in end-stage renal failure patients undergoing peritoneal dialysis.
    Ndlovu KCZ; Swe Swe-Han K; Assounga A
    Ren Fail; 2019 Nov; 41(1):303-313. PubMed ID: 30991864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal carriage and peritonitis by Staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study.
    Wanten GJ; van Oost P; Schneeberger PM; Koolen MI
    Perit Dial Int; 1996; 16(4):352-6. PubMed ID: 8863325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal mupirocin does not prevent exit-site infections in children receiving peritoneal dialysis.
    Araki Y; Hataya H; Ikeda M; Ishikura K; Honda M
    Perit Dial Int; 2003; 23(3):267-9. PubMed ID: 12938828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.
    Thodis E; Bhaskaran S; Pasadakis P; Bargman JM; Vas SI; Oreopoulos DG
    Perit Dial Int; 1998; 18(3):261-70. PubMed ID: 9663889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD.
    Lye WC; Leong SO; Lee EJ
    Kidney Int; 1993 Jun; 43(6):1357-62. PubMed ID: 8315950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.
    Luzar MA; Coles GA; Faller B; Slingeneyer A; Dah GD; Briat C; Wone C; Knefati Y; Kessler M; Peluso F
    N Engl J Med; 1990 Feb; 322(8):505-9. PubMed ID: 2300122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.
    Sesso R; Parisio K; Dalboni A; Rabelo T; Barbosa D; Cendoroglo M; Pignatari A; Draibe S; Ajzen H
    Clin Nephrol; 1994 Jun; 41(6):370-6. PubMed ID: 8076441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis.
    Kingwatanakul P; Warady BA
    Adv Perit Dial; 1997; 13():281-4. PubMed ID: 9360700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal carriage of Staph. aureus in peritonitis and exit-site infections.
    De Vecchi AF; Morelli JM; Mascheroni E; Parolari R; Capaccio P; Scaramellini G
    Perit Dial Int; 1997; 17(2):205-7. PubMed ID: 9159847
    [No Abstract]   [Full Text] [Related]  

  • 13. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centres in Denmark. The Danish Study Group of Peritonitis in Dialysis (DASPID).
    Zimakoff J; Bangsgaard Pedersen F; Bergen L; Baagø-Nielsen J; Daldorph B; Espersen F; Gahrn Hansen B; Høiby N; Jepsen OB; Joffe P; Kolmos HJ; Klausen M; Kristoffersen K; Ladefoged J; Olesen-Larsen S; Rosdahl VT; Scheibel J; Storm B; Tofte-Jensen P
    J Hosp Infect; 1996 Aug; 33(4):289-300. PubMed ID: 8864941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for peritoneal dialysis-related infections.
    Oxton LL; Zimmerman SW; Roecker EB; Wakeen M
    Perit Dial Int; 1994; 14(2):137-44. PubMed ID: 8043666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients.
    Vychytil A; Lorenz M; Schneider B; Hörl WH; Haag-Weber M
    J Am Soc Nephrol; 1998 Apr; 9(4):669-76. PubMed ID: 9555670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does catheter immobilization reduce exit-site infections in CAPD patients?
    Turner K; Edgar D; Hair M; Uttley L; Sternland R; Hunt L; Gokal R
    Adv Perit Dial; 1992; 8():265-8. PubMed ID: 1361803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience.
    Cavdar C; Zeybel M; Atay T; Sifil A; Sanlidag C; Gulay Z; Camsari T
    Adv Perit Dial; 2004; 20():62-6. PubMed ID: 15384797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis.
    Sesso R; Draibe S; Castelo A; Sato I; Leme I; Barbosa D; Ramos O
    Clin Nephrol; 1989 May; 31(5):264-8. PubMed ID: 2736815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
    Thodis E; Passadakis P; Panagoutsos S; Bacharaki D; Euthimiadou A; Vargemezis V
    Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.
    Bernardini J; Piraino B; Holley J; Johnston JR; Lutes R
    Am J Kidney Dis; 1996 May; 27(5):695-700. PubMed ID: 8629630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.